{"doi":"10.1016/j.celrep.2023.112307","title":"The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2","abstract":"Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Vaccines remain successful at limiting severe disease and death, but the potential for further coronavirus zoonosis motivates the search for pan-coronavirus vaccines. This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins. Here, we compare the structure of 12 sarbecovirus glycan shields. Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses. However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165. Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density. The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.","journal":"Cell Reports","year":2023,"id":330959,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":32,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.955,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":996559,"name":"Dylan P. Ivory","orcid":"0000-0003-0263-6726","position":1,"is_corresponding":false},{"id":527092,"name":"Ge Song","orcid":"0000-0001-7306-3510","position":2,"is_corresponding":false},{"id":550369,"name":"Wanting He","orcid":"0000-0003-4692-3516","position":3,"is_corresponding":false},{"id":810317,"name":"Tazio Capozzola","orcid":"0000-0002-7269-588X","position":4,"is_corresponding":false},{"id":653277,"name":"Peter Yong","orcid":"0000-0002-4899-3270","position":5,"is_corresponding":false},{"id":108980,"name":"Dennis R. Burton","orcid":"0000-0001-6711-9864","position":6,"is_corresponding":false},{"id":294229,"name":"Raiees Andrabi","orcid":"0000-0001-8837-7520","position":7,"is_corresponding":false},{"id":105401,"name":"Max Crispin","orcid":"0000-0002-1072-2694","position":8,"is_corresponding":false},{"id":105400,"name":"Joel D. Allen","orcid":"0000-0003-2547-968X","position":0,"is_corresponding":true}],"reference_count":63,"raw_metadata":null,"created_at":"2026-07-19T01:09:14.691473Z","pmid":"36972173","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}